Claris Law Legal Blogging Community

Editor: Tim O'Brien
Profession: Attorney at Law

As I go through the FDA files, it truly amazes me that the Fosamax problem has flown under the radar for so long. The FDA first approved Fosamax for use in 1995. By 1996, Fosamax's first year on the market, Fosamax was the leader in the number of adverse event reports received by the FDA! Look at the following report from the FDA, specifically TABLE 4: "Postmarket ADE Reports by Top-10 Ranked Suspect Drugs": http://www.fda.gov/cder/dpe/annrep96/ You will see that, out of all the hundreds of thousands of Rx drugs on the market, Merck's Fosamax had 3.5% of all reported adverse events and, as a result, occupied the unenviable pole position for prescription AERs.